Author:
Gisselbrecht C.,Glass B.,Laurent G.,Gill D. S.,Linch M. D.,Trneny M.,Bron D.,Shpilberg O.,Hagberg H.,Bargetzi M.,Ma D.,Briere J.,Moskowitz C.,Schmitz N.
Publisher
American Society of Clinical Oncology (ASCO)
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab;International Reviews of Immunology;2017-08-11
2. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial;Leukemia & Lymphoma;2015-02-26
3. Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial;Journal of Clinical Oncology;2013-05-01
4. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma;Biology of Blood and Marrow Transplantation;2013-01
5. Diffuse Large B-Cell Lymphoma;Lymphoma;2013